National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cost Effectiveness of ambrisentan (Volibris®) in the treatment of patients with Functional Class II or III pulmonary arterial hypertension.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
October 2008 February 2009  

A summary of the report that was prepared by the National Centre for Pharmacoeconomics and submitted to the HSE is included in the attached document.

Ambrisentan (Volibris) summary

 

July 2014

In accordance with the Health Act (Pricing and Supply of Medical Goods) 2013 (section 18(4)), the HSE has requested the NCPE to re-examine the cost effectiveness of ambrisentan (Volibris®).

Rapid Review

Commenced Completed Outcome
27/05/2014 04/07/2014 Full Pharmacoeconomic Evaluation not Recommended.